551 related articles for article (PubMed ID: 18996035)
1. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
[TBL] [Abstract][Full Text] [Related]
2. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
Tao ZF; Fu WJ; Chen YB; Yuan ZG; Wang DX; Hou J
Ai Zheng; 2006 Apr; 25(4):461-4. PubMed ID: 16613681
[TBL] [Abstract][Full Text] [Related]
3. International staging system for multiple myeloma.
Greipp PR; San Miguel J; Durie BG; Crowley JJ; Barlogie B; Bladé J; Boccadoro M; Child JA; Avet-Loiseau H; Kyle RA; Lahuerta JJ; Ludwig H; Morgan G; Powles R; Shimizu K; Shustik C; Sonneveld P; Tosi P; Turesson I; Westin J
J Clin Oncol; 2005 May; 23(15):3412-20. PubMed ID: 15809451
[TBL] [Abstract][Full Text] [Related]
4. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
Molica S; Vitelli G; Mirabelli R; Digiesu G; Giannarelli D; Cuneo A; Ribatti D; Vacca A
Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271
[TBL] [Abstract][Full Text] [Related]
5. International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy.
Scudla V; Zemanova M; Minarik J; Bacovsky J; Ordeltova M; Indrak K; Budikova M; Dusek L; Farbiakova V
Neoplasma; 2006; 53(4):277-84. PubMed ID: 16830053
[TBL] [Abstract][Full Text] [Related]
6. Circulating angiogenic cytokines in multiple myeloma and related disorders.
Urba ska-Rys H; Wierzbowska A; Robak T
Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors and staging systems of multiple myeloma:
Tao ZF; Fu WJ; Yuan ZG; Wang DX; Chen YB; Hou J
Chin Med J (Engl); 2007 Oct; 120(19):1655-8. PubMed ID: 17935664
[TBL] [Abstract][Full Text] [Related]
8. [Prognostic value of the new international staging system in multiple myeloma. Comparison with Durie-Salmon staging system].
Conté L G; Figueroa M G; Lois V V; Cabrera C ME; León R A; García L H; Rojas R H
Rev Med Chil; 2008 Jan; 136(1):7-12. PubMed ID: 18483648
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].
Deng SH; Xu Y; Mai YJ; Wang YF; Zhao YZ; Zou DH; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):217-21. PubMed ID: 18843972
[TBL] [Abstract][Full Text] [Related]
10. Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma.
Ailawadhi S; Abdelhalim AN; Derby L; Mashtare TL; Miller KC; Wilding GE; Alberico RA; Gottlieb R; Klippenstein DL; Lee K; Chanan-Khan AA
Cancer; 2010 Jan; 116(1):84-92. PubMed ID: 19862816
[TBL] [Abstract][Full Text] [Related]
11. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance.
Leleu X; Le Friec G; Facon T; Amiot L; Fauchet R; Hennache B; Coiteux V; Yakoub-Agha I; Dubucquoi S; Avet-Loiseau H; Mathiot C; Bataille R; Mary JY;
Clin Cancer Res; 2005 Oct; 11(20):7297-303. PubMed ID: 16243800
[TBL] [Abstract][Full Text] [Related]
12. Classification and prognostic evaluation in multiple myeloma. A retrospective study of relationship of survivals and responses to chemotherapy to immunological types, 20 single prognostic factors, 15 clinical staging systems, and 6 morphological classifications.
Pasqualetti P; Colantonio D; Collacciani A; Casale R; Natali G
Panminerva Med; 1991; 33(2):93-110. PubMed ID: 1923560
[TBL] [Abstract][Full Text] [Related]
13. Erythropoiesis-stimulating agents are associated with reduced survival in patients with multiple myeloma.
Katodritou E; Verrou E; Hadjiaggelidou C; Gastari V; Laschos K; Kontovinis L; Kapetanos D; Constantinou N; Terpos E; Zervas K
Am J Hematol; 2008 Sep; 83(9):697-701. PubMed ID: 18626886
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in multiple myeloma: selection using Cox's proportional hazard model.
Pasqualetti P; Collacciani A; Maccarone C; Casale R
Biomed Pharmacother; 1996; 50(1):29-35. PubMed ID: 8672729
[TBL] [Abstract][Full Text] [Related]
15. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M
Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic importance of beta-2-microglobulin in multiple myeloma].
Avilés A; Zepeda G; Guzmán R; Talavera A; García EL; Díaz-Maqueo JC
Rev Invest Clin; 1992; 44(2):215-20. PubMed ID: 1439309
[TBL] [Abstract][Full Text] [Related]
17. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
Alexandrakis MG; Passam FH; Sfiridaki A; Kandidaki E; Roussou P; Kyriakou DS
Am J Hematol; 2003 Apr; 72(4):229-33. PubMed ID: 12666132
[TBL] [Abstract][Full Text] [Related]
18. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with multiple myeloma.
Takada S; Morita K; Hayashi K; Matsushima T; Sawamura M; Murakami H; Nojima Y
Eur J Haematol; 2005 Dec; 75(6):505-10. PubMed ID: 16313263
[TBL] [Abstract][Full Text] [Related]
19. Chronic kidney disease stage 5 as the prognostic complement of International Staging System for multiple myeloma.
Hsiao LT; Yang CF; Yang SH; Gau JP; Yu YB; Hong YC; Liu CY; Liu JH; Chen PM; Chiou TJ; Tzeng CH
Eur J Haematol; 2012 Feb; 88(2):159-66. PubMed ID: 21973045
[TBL] [Abstract][Full Text] [Related]
20. [Prognostic evaluation in multiple myeloma. Relationship between immunological types, single prognostic factors, clinical staging systems, morphological classification systems and survival].
Pasqualetti P; Colantonio D; Casale R; Di Lauro G; Collacciani A; Festuccia V; Trotta A; Natali G
Ann Ital Med Int; 1990; 5(3 Pt 1):195-204. PubMed ID: 2288822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]